




QUA VADIS mRNA? Innovation for sustainability.

Prof Petro Terblanche Afrigen

mRNA Companies and Locations: Evolving at speed.





© Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, OpenStreetMap, TomTom

www.beacon-intelligence.com

mRNA Disease Landscape-What's Next?

Solid Tumours Infectious Diseases Blood Cancers Metabolic Diseases Genetic Disorders







www.beacon-intelligence.com hansonwade

The mRNA Disease Vaccines in Descending order of Sponsors (global data)


40











RECOGNITION AND APPRECIATION

AFRICA CDC

medicines

patent

pool

African (

WHO.

Medicines Patent Pool(MPP). Funders: France, Belgium, Germany, Norway, Canada, Switzerland, Alma Foundation, South Africa, EC/EU. SA Government DSL SAMRC and SAMVAC consortium. Biovac. Civil Society Groups. mRNA Hub Steering Committee. mRNA Hub Scientific Advisory Committee. PATH. NIH/VRC. Curapath. Equipment and technology suppliers. University of the Witwatersrand, NICD, CeBER-UCT, PCDDP NWU, and other SA Universities. Afrigen Team and Supporting Stakeholders and Shareholders.



World Health

Organization

Bi

🕚 torlak

C DARNITSA

and ages from

SINERGIUM Biotech

BOV/X

Institut Poster

POLYVAC

P